GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PixarBio Corp (GREY:PXRB) » Definitions » Total Current Liabilities

PXRB (PixarBio) Total Current Liabilities : $0.01 Mil (As of Sep. 2016)


View and export this data going back to 2016. Start your Free Trial

What is PixarBio Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. PixarBio's total current liabilities for the quarter that ended in Sep. 2016 was $0.01

PixarBio Total Current Liabilities Historical Data

The historical data trend for PixarBio's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PixarBio Total Current Liabilities Chart

PixarBio Annual Data
Trend Dec14 Dec15
Total Current Liabilities
0.03 0.09

PixarBio Quarterly Data
Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.09 0.13 0.18 0.01

PixarBio Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

PixarBio's Total Current Liabilities for the fiscal year that ended in Dec. 2015 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.091+0
+Other Current Liabilities+Current Deferred Liabilities
=-0.001+0
=0.09

PixarBio's Total Current Liabilities for the quarter that ended in Sep. 2016 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.005+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

PixarBio Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of PixarBio's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

PixarBio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PixarBio Corp (GREY:PXRB) » Definitions » Total Current Liabilities
Comparable Companies
VSAR ARCT ASX:ZLD TSXV:ATE ASX:ANR XPAR:OSE NTRP OSL:HBC XKRX:216400 LSE:HVO OSTO:ACTI BCLI LSE:SCLP ROCO:6580 ASX:BOT LSE:RLM NBY ASX:AHZ NAVB SPHS
Traded in Other Exchanges
N/A
Address
200 Boston Avenue, Suite 1875, Medford, MA, USA, 02155
Website
https://www.pixarbio.com
PixarBio Corp is a specialty pharmaceutical company focused on preclinical and clinical commercial development of therapeutic drug delivery systems for post-operative pain. The company's lead clinical candidate, NeuroRelease is a non-opioid / non-opiate preclinical stage product intended for the treatment of surgical pain, with planned future indications for chronic pain. NeuroRelease blocks nociceptive and neuropathic pain signals arising from temperature and pressure stimuli without affecting motor function, which is intended to allow for effective treatment without delaying post-surgical physical therapy.

PixarBio Headlines